Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 4/20 | 0.77 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070622 | 0.88 | PDE4D (0.76) | PDE4DPDE4BRAB9AMAPTNPC1 | |
| SCHEMBL2199384 | 0.88 | PDE4D (0.67) | PDE4DPDE4BRAB9AMAPTNPC1 | |
| SCHEMBL2200071 | 0.87 | PDE4D (0.74) | PDE4DPDE4BRAB9AMAPTNPC1 | |
| SCHEMBL4312926 | 0.87 | PDE4D (1.00) | PDE4DPDE4BRAB9AMAPTNPC1 | |
| SCHEMBL6069484 | 0.86 | PDE4D (0.72) | PDE4DPDE4BRAB9AMAPTNPC1 | |
| SCHEMBL6070540 | 0.86 | PDE4D (0.72) | PDE4DPDE4BRAB9AMAPTNPC1 | |
| SCHEMBL6070211 | 0.86 | PDE4D (0.73) | PDE4DPDE4BRAB9AMAPTNPC1 | |
| SCHEMBL20213756 | 0.85 | ALDH1A1 (0.77) | PDE4DPDE4BRAB9AMAPTNPC1 | |
| SCHEMBL6069548 | 0.85 | PDE4D (1.00) | PDE4DPDE4BRAB9AMAPTNPC1 | |
| SCHEMBL20502220 | 0.85 | PDE4D (0.74) | PDE4DPDE4BRAB9AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087634-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2006-08-08 | — | — | US | claimed |
| US-20030236412-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2003-12-25 | — | — | US | claimed |
| US-6569885-B1 | Such as 1-(4-bromophenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid ethyl ester; side effect reduction; for treatment of central nervous system disorders | ICOS CORPORATION | 2003-05-27 | — | — | US | claimed |
| WO-2024102639-A1 | N-ARYLPYRAZOLE NOD2 AGONISTS AS PROMOTERS OF IMMUNE CHECKPOINT INHIBITOR THERAPY | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-05-16 | — | — | WO | disclosed |
| US-7087634-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| US-20030236412-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2003-12-25 | — | — | US | disclosed |
| US-6569885-B1 | Such as 1-(4-bromophenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid ethyl ester; side effect reduction; for treatment of central nervous system disorders | ICOS CORPORATION | 2003-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236412-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | PDE4A, PDE4B, PDE7A | PDE4D 5/4885PDE4B 2/4885RAB9A 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.